RARE:NASDAQ
Ultragenyx Pharmaceutical Inc
16,08 US$
arrow_downward
-1,17%(-0,19) 1D
13 ნოე, 16:00:00 GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for RARE...
Open
16,30 US$
High
16,32 US$
Low
15,85 US$
Mkt. cap
1,64 მლრდ.
Avg. vol.
3,71 მლნ.
Volume
1,68 მლნ.
52-wk high
39,89 US$
52-wk low
12,73 US$
EPS
-5,19 US$
Beta
0,37
Shares outstanding
101,92 მლნ.
No. of employees
1 ათ.
Open
16,30 US$
High
16,32 US$
Low
15,85 US$
Mkt. cap
1,64 მლრდ.
Avg. vol.
3,71 მლნ.
Volume
1,68 მლნ.
52-wk high
39,89 US$
52-wk low
12,73 US$
EPS
-5,19 US$
Beta
0,37
Shares outstanding
101,92 მლნ.
No. of employees
1 ათ.
News stories
From web sources and news partners
TradingView
·
1 საათის წინ
SpaceX's S&P 500 bid gets new life as Elon Musk pitches Tesla merger
Benzinga
·
1 საათის წინ
S&P 500 Rout Exposes Hidden Risk In 10% Buffered ETFs
The Motley Fool
·
4 საათის წინ
Prediction: This Small-Cap Value ETF Will Beat the S&P 500 Over the Next 10 Years
Traders Union
·
59 წუთის წინ
Michael Kantro: Institutional investors focus on stock picking as S&P 500 targets have lost relevance
Profile
Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.
Ultragenyx is based in Novato, CA and Brisbane, CA and has a presence in the Boston area, including a gene therapy plant under construction as of 2021. The company’s Latin American headquarters is located in Miami.
Ultragenyx collaborates on product development with other companies including GeneTX, Kyowa Hakko Kirin, Mereo Biopharma and Daiichi Sankyo. Ultragenyx has three products Burosumab, Triheptanoin and Vestronidase alfa that have received FDA approval and several others currently in clinical trials. The company also holds the non-US commercial rights to Regeneron’s evinacumab-dgnb, which is approved by the FDA and EMA. Wikipedia
About Ultragenyx Pharmaceutical Inc
CEOემილ კაკისი
Employees1,37 ათ.
Founded2010
HeadquartersNovato, კალიფორნია, ამერიკის შეერთებული შტატები
SectorHealth Care
Industry-
Websiteultragenyx.com